Delayed Nyse  -  04:03 2022-06-29 pm EDT
92.51 USD   +0.67%
07:03aMerck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market
06:46aMerck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28
06/28AstraZeneca and Merck - LYNPARZA (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck Announces Third-Quarter 2022 Dividend

05/24/2022 | 01:47pm EDT

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.69 per share of the company’s common stock for the third quarter of 2022. Payment will be made on July 8, 2022 to shareholders of record at the close of business on June 15, 2022.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (

ę Business Wire 2022
All news about MERCK & CO., INC.
07:03aMerck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Star..
06:46aMerck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28
06/28AstraZeneca and Merck - LYNPARZA (olaparib) Receives Positive Opinion From EU CHMP as A..
06/28Merck to Supply Keytruda for Solid Tumors Clinical Trial Collaboration With Transgene, ..
06/28Merck & Co. to Supply Keytruda Drug for Transgene, BioInvent's Clinical Study in Solid ..
06/27Merck - European Commission Approves KEYTRUDA (pembrolizumab) as Adjuvant Treatment for..
06/27Cowen Adjusts Merck's Price Target to $102 From $95, Maintains Market Perform Rating
06/27European Union Recommends AstraZeneca and MSD's Lynparza for Marketing Authorisation
06/27Merck, AstraZeneca's Lynparza Obtains EMA's Committee Recommendation as Adjuvant Treatm..
06/27LYNPARZA« (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for G..
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2022 57 916 M - -
Net income 2022 15 536 M - -
Net Debt 2022 17 983 M - -
P/E ratio 2022 15,1x
Yield 2022 3,06%
Capitalization 232 B 232 B -
EV / Sales 2022 4,32x
EV / Sales 2023 4,26x
Nbr of Employees 67 500
Free-Float 70,6%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 92,51 $
Average target price 96,59 $
Spread / Average Target 4,41%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Dave Williams EVP, Chief Information & Digital Officer
Lisa LeCointe-Cephas Chief Ethics & Compliance Officer, SVP
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.19.90%232 372
JOHNSON & JOHNSON6.46%465 600
PFIZER, INC.-12.14%284 248
ROCHE HOLDING AG-16.24%270 886
ABBVIE INC.12.62%269 467